Provided herein are antioxidant, thermally-responsive polymeric compositions and methods of making and using the compositions, e.g., for treatment of ischemia reperfusion injury or radiation exposure.

Provided herein are antioxidant, thermally-responsive polymeric compositions and methods of making and using the compositions, e.g., for treatment of ischemia reperfusion injury or radiation exposure.

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

A pharmaceutical composition for treating skin infections is described herein. A method using a pharmaceutical composition for treating skin infections is described herein. A pharmaceutical composition for treating skin infections may comprise, in 100 parts of the composition, 1-99 parts of a pharmaceutically acceptable excipient; 99-1 parts of a keratolytic; 99-1 parts ethyl pyruvate; and 99-1 parts povidone iodine. A method for treating skin infections may comprise topical application of a composition to an infected skin cell for a treatment period.

Aspects of the present disclosure relate to a method of preventing transmission of an enveloped RNA virus. The method includes applying to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan. The first mammalian subject not substantially colonized by the enveloped RNA virus interacts with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction, the second viral load is no greater than 0.5 log increase over an initial viral load over a duration of the treatment plan. The mucosal tissue is in the nasopharynx, nasal cavity, or anterior nares of the mammalian subject. The antiseptic composition comprises iodine, iodophor, or combinations thereof.

Aspects of the present disclosure relate to a method of preventing transmission of an enveloped RNA virus. The method includes applying to a mucosal tissue of a first mammalian subject not substantially colonized by the enveloped RNA virus an effective amount of an antiseptic composition or a pharmaceutically acceptable salt thereof according to a treatment plan. The first mammalian subject not substantially colonized by the enveloped RNA virus interacts with a second mammalian subject colonized by the enveloped RNA virus at a first viral load, the first mammalian subject has a second viral load based on the interaction, the second viral load is no greater than 0.5 log increase over an initial viral load over a duration of the treatment plan. The mucosal tissue is in the nasopharynx, nasal cavity, or anterior nares of the mammalian subject. The antiseptic composition comprises iodine, iodophor, or combinations thereof.

The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method, and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.

The invention provides a method of inducing satiety in a subject comprising a step of orally administering a composition comprising an effective amount of a first agent capable of inducing satiety and of a second agent capable of augmenting the satiety-inducing effect of the first agent. Also disclosed are compositions for carrying out the method, and a body weight management system comprising such compositions in combination with a device configured for the collection, storage and/or display of information relating to a subject's response to a predefined therapeutic regimen of orally administering the composition.